Results 231 to 240 of about 11,705,271 (311)
Expert consensus on the use of oral antiseptics in oral surgery: Evidence-based clinical practice guidelines. [PDF]
Sánchez-Torres A +6 more
europepmc +1 more source
Anticoagulation Treatment Response Among Phenotypic ESUS Clusters: Evidence From CASPR
ABSTRACT Objective To evaluate treatment effect heterogeneity across phenotypic clusters of patients with cryptogenic embolic stroke using causal inference methods. Methods From a retrospective, multicenter cohort of patients with cryptogenic embolic stroke, we estimated the treatment effect of anticoagulation versus antiplatelet therapy in patients ...
Elena Badillo Goicoechea +53 more
wiley +1 more source
Clinical Practice Guidelines in Dentistry
Elliot Abt +4 more
doaj +1 more source
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley +1 more source
ASSOBRAFIR clinical practice guidelines in intensive care physical therapy: Rehabilitation strategies in critically ill adults. [PDF]
Neto SGB +28 more
europepmc +1 more source
ABSTRACT Objective To compare the incidence of diabetes mellitus and its associations with hospitalisation and mortality in adults with multiple sclerosis (MS) and matched controls. Methods Using English primary care data from the Clinical Practice Research Datalink, linked to hospital and mortality records, we matched adults with MS with up to 10 ...
Yolanda Lau +8 more
wiley +1 more source
Korean Clinical Practice Guidelines for Interstitial Lung Disease: Part 2. Idiopathic Pulmonary Fibrosis. [PDF]
Choi HS +8 more
europepmc +1 more source
Stage‐Specific Patterns of Imaging and Non‐Motor Biomarkers in Spinocerebellar Ataxia Type 3
ABSTRACT Objective Advancements in disease‐modifying therapies for spinocerebellar ataxia Type 3 (SCA3) underscore the need for robust biomarkers to monitor disease progression and evaluate treatment efficacy. Although motor phenotypes have been well characterized, less is known about non‐motor and imaging‐based features across different disease stages.
Chun Li +17 more
wiley +1 more source

